Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Revenue (2021 - 2025)

InMed Pharmaceuticals has reported Revenue over the past 5 years, most recently at $820188.0 for Q4 2025.

  • For Q4 2025, Revenue fell 26.22% year-over-year to $820188.0; the TTM value through Dec 2025 reached $4.5 million, down 6.73%, while the annual FY2025 figure was $4.9 million, 7.5% up from the prior year.
  • Revenue for Q4 2025 was $820188.0 at InMed Pharmaceuticals, down from $1.1 million in the prior quarter.
  • Over five years, Revenue peaked at $2.3 million in Q2 2023 and troughed at $265092.0 in Q4 2021.
  • A 5-year average of $982686.4 and a median of $1.1 million in 2024 define the central range for Revenue.
  • Biggest five-year swings in Revenue: soared 348.96% in 2023 and later tumbled 44.48% in 2024.
  • Year by year, Revenue stood at $265092.0 in 2021, then skyrocketed by 77.22% to $469783.0 in 2022, then soared by 163.99% to $1.2 million in 2023, then fell by 10.36% to $1.1 million in 2024, then dropped by 26.22% to $820188.0 in 2025.
  • Business Quant data shows Revenue for INM at $820188.0 in Q4 2025, $1.1 million in Q3 2025, and $1.3 million in Q2 2025.